We use cookies to ensure the best user experience. By using the page, you accept the usage of cookies. Read more about cookies
Skip to Content
FI
SV
EN
  • Front page
  • For public
  • Databases and registers
  • Development and HTA
  • Marketing Authorisations
  • Medical devices
  • Pharmaceutical safety and information
  • Pharmacies
  • Supervision
  • Veterinary
  • About us
    • Contact us
    • Forms
    • Organisation
    • What's new
      • News archive
      • Brexit
      • EU Presidency 2019
      • Coronavirus (COVID-19)
    • Publications
    • Fees
    • Estimated processing times
    • Frequently asked questions
    • Open positions
    • Open data
fimea.fi front page fimea.fi front page

SearchBar

  • page search

  • medicine search

Move to advanced medicine search
Medicine search
Contact Information
FI
SV
EN
About us
  •  fimea.fi
    • For public
      • Fimea’s services to citizens
        • Cooperation with patient associations
      • What is a medicine?
        • Generic substitution
        • Generic products
      • What is a food supplement?
      • Safety of medicines
        • Monitoring the safety of medicinal products
        • Adverse reactions
        • Submitting a report on an adverse reaction
        • Medicinal products under additional monitoring
        • Product defects
        • Drug interactions
        • Pharmaceutical injuries
      • Correct use of medicines
        • Ensure the safety of your medication
        • Monitor the effects of your medication
        • How to store medicines?
        • How should medicines be disposed of?
      • List of medicines
      • Where can I find reliable information about medicines?
        • How can I assess the reliability of drug information?
        • Medicinal product packs
        • Package leaflet
      • How are medicines supplied to users in Finland?
        • What factors affect the availability of medicines?
        • Why might a pharmacy run out of my medicine?
        • Obligatory storing of medicines
        • Exemptions and special permits
      • Ordering medicines online
        • Why is the food supplement I ordered considered to be a medicine?
      • Bringing medicines to Finland
      • What medicines can I bring abroad?
      • Falsified medicines
      • Pain relievers and self-care
      • Medicines and pregnancy
      • Medicines for children
        • Developing better medicines for children
      • Medication of the elderly
      • Vaccines
      • Influenza
        • Influenza vaccinations
        • Antiviral medication
        • Pandemic
    • Databases and registers
      • FimeaWeb
      • Meds75+
      • Consumption
      • Self-medication products
      • Basic register
        • Plasma-derived products with marketing authorisation
      • Substitutable medicinal products
        • Textfile for databases
        • Criteria used in compiling the list
      • Consumption information
      • ATC codes
      • Shortages
    • Development and HTA
      • Assessment of pharmacotherapies (HTA)
        • Assessment of hospital-only medicinal products
        • Topic selection
        • Nordic collaboration (FINOSE)
        • Assessment reports (in Finnish)
      • Research
        • Research Network for Rational Pharmacotherapy (RATTI)
      • Medicines information
        • Medicines Information Network
        • High-quality medicines information
      • Interprofessional network
      • Patient advisory board
    • Marketing Authorisations
      • Marketing authorisation application
        • Finland as a Reference Member State in the decentralised procedure (DCP)
        • Finland as a Reference Member State in the Mutual Recognition / Repeat Use Procedure (MRP/RUP)
        • Changing of Reference Member State duties to Finland
        • Finland as a rapporteur in the centralised marketing authorisation procedure (CP)
        • Granted and cancelled marketing authorisations
        • Pending marketing authorisation applications
        • Biological Medicinal Products
        • Orphan drugs
        • Paediatric medicines
        • European Pharmacopoeia
        • Active substance names and standard terms
      • Renewals and variation applications
        • Renewals
        • Variation applications
        • Changes to labelling
        • Transferring a marketing authorisation to a new holder
        • Article 5 classification requests for variation applications
        • OTC application
      • Product Information
        • Summary of product characteristics
        • Package leaflet
        • Package labelling
        • Text templates
        • Braille and package leaflets for the visually impaired
        • Trade names of medicinal products
        • Strength
        • Translating influenza vaccines in Finland
      • Electronic marketing authorisation submissions
        • What's new
        • Instructions for electronic marketing authorisation submissions
        • Special characteristics of the electronic marketing authorisation process for veterinary medicines
      • Cancelling a marketing authorisation or registration and sunset clause
        • Cancelling a marketing authorisation or registration
        • Expiration of marketing authorisations and registrations (sunset clause)
        • Sunset clause - concepts
        • Sunset clause exemption
        • List of expired marketing authorisations and registrations
      • Introduction to market
      • Parallel import
      • Herbal remedies and medicinal products
        • Herbal medicinal products
        • Traditional herbal medicinal products
        • Homeopathic and anthroposophic preparations
      • Innovation Office
        • Informal Regulatory Guidance
        • Scientific Advice
      • Interchangeable medicinal products
      • Safety features
      • Other permits
        • Exemption
      • Frequently asked questions - marketing authorisations
        • Summary of Product Characteristics is to be available also in Swedish
        • Local representative
    • Medical devices
      • Export
      • Legislation
      • Placing on the market
      • Clinical investigation
      • Registration
      • Incident reporting
      • Language requirements
      • Brexit and the availability of medical devices
      • Market surveillance programmes
    • Pharmaceutical safety and information
      • Pharmaceutical safety
        • Reporting adverse reactions
      • Biological medicinal products
      • Biosimilars
        • Biosimilars in Finland
      • Regulation on Medicinal Products for Paediatric Use
        • Paediatric Committee
        • Paediatric Investigation Plan
        • Coordination and communication
        • Rewards and incentives
        • Symbol in the labels of medicinal products
    • Pharmacies
      • Pharmacy licences
        • How to apply for a pharmacy licence
        • Supervision Committee
      • Pharmacy tax
      • Special permits
        • How to apply for a special permit
        • Temporary special permit products
      • Manufacturing medicinal products
      • Schengen certificates
      • PIC/S GMP Guide
      • Dose-dispensing
    • Supervision
      • Pharmacovigilance
        • ICSR reporting to the EudraVigilance system
        • Product defects
        • Summaries of risk management plans
        • Fimea's Instructions to the National Implementation of the Directive 2010/84/EU
        • Product-specific risk minimisation material
      • Clinical Drug Trials
        • Notification of a clinical trial - EudraCT
        • Serious Unexpected Adverse Reactions in Clinical Trials (SUSARs)
        • EU Regulation 536/2014
          • What's new
      • Advertising of medicinal products
      • Classification
        • Principles of classification
        • Classification application
        • List of medicines
        • After classification
        • Private imports of medicinal products
      • Pharmaceutical industry
        • Licenses
          • Local pharmaceutical wholesale license holders
        • Registered brokers of medicinal products
      • Good Laboratory Practice (GLP)
      • Mandatory reserve supplies
        • Reports on quantities to be stocked as mandatory reserve supplies
        • List of products to be stocked as mandatory reserve supplies
        • Application for exemption to maintain lower stock levels
        • Special arrangements for fulfilment of the obligation to maintain mandatory reserve supplies
      • Establishments
        • Supervising blood services
        • Supervising tissue establishments
        • Supervision of organ activity
      • Certificates of a Pharmaceutical Product (CPP)
        • Applying for an export certificate
      • Narcotics control
        • Additional information to be submitted with narcotics licence applications
      • Batch-specific control
      • GMP certificates
      • Laboratory of Fimea
        • National and international collaboration
      • Legislation
        • International and EU legislation
        • European Pharmacopoeia
          • National pharmacopoeia documents
          • To users of the Pharmacopoeia
          • CEP Procedure
          • International Non-proprietary Names for Pharmaceutical Substances (INN)
        • National laws
        • Administrative regulations
        • Normative guidelines
        • Other guidelines
    • Veterinary
      • Marketing authorisation procedures
      • Special permits for compassionate use
        • Applying for special permit
        • FAQ
          • A Questions and answers on how to fill in the form
          • B Questions and answers regarding the technical aspects of permit application
          • C Questions and answers regarding the decision and the processing of the application
          • D Other questions and answers
        • Lists of veterinary medicinal products
      • Adverse effects
      • Consumption of veterinary antimicrobials
        • The European Surveillance of Veterinary Antimicrobial Consumption ESVAC
      • Clinical trials on veterinary medicinal products
        • Immunological products
      • Withdrawal period and MRL
        • What is a withdrawal period?
        • MRL
        • Horses as food-producing animals
      • Private import
    • About us
      • Contact us
        • Change of address
        • Copyright
        • Contact
        • Personnel
        • Secure Mail
      • Forms
      • Organisation
        • Strategy
          • Our goals
          • Strategic framework
        • International representation
        • Fimea committees
      • What's new
        • News archive
        • Brexit
        • EU Presidency 2019
        • Coronavirus (COVID-19)
          • Frequently asked questions (COVID-19)
          • Adverse reactions reported on corona vaccines
      • Publications
      • Fees
      • Estimated processing times
      • Frequently asked questions
        • Clinical drug trials
        • Generic medicines
        • Invoicing
        • Marketing authorisations
          • Summary of Product Characteristics is to be available also in Swedish
        • Narcotics control
        • New EudraVigilance -system
      • Open positions
      • Open data
  • fimea.fi
  • About us
  • What's new

What's new

Suomeksi ⁄ På svenska

News

25.2.2021 Fimea's new strategy focuses on cooperation and development

17.2.2021 Training modules for the Clinical Trials Information System (CTIS) portal have been published

27.1.2021 Webpage detailing adverse reaction reports of corona vaccines has been opened

26.1.2021 Fimea told of first deaths among recipients of COVID-19 vaccine

21.1.2021 Reminder: EMA to organise CTIS programme training for non-commercial operators

18.1.2021 Fimea and THL closely monitor adverse effects and safety of coronavirus vaccines – no unexpected side effects have emerged

18.1.2021 Report on medicines data repository completed

12.1.2021 Brexit agreement and pharmaceutical imports from 1.1.2021

5.1.2021 Coronavirus vaccines are introduced in the EU through the marketing authorisation process

31.12.2020 Medicines cannot be purchased from Great Britain by mail starting from 1 January 2021

Show all

  • fimea.fi
  • About us
  • What's new
  • Front page
  • For public
  • Databases and registers
  • Development and HTA
  • Marketing Authorisations
  • Medical devices
  • Pharmaceutical safety and information
  • Pharmacies
  • Supervision
  • Veterinary
  • About us
  • Contact us
  • Frequently asked questions
  • Forms
fimea
  • Twitter
P.O. Box 55, FI-00034 FIMEA, FINLAND
Switchboard: +358 29 522 3341
firstname.lastname@fimea.fi
© Fimea 2020
Ad­min­is­trat­ive sec­tor of the Min­istry of So­cial Af­fairs and Health
The Finnish Medicines Agency Fimea is the national competent authority for regulating pharmaceuticals. As a central administrative agency operating under the Ministry of Social Affairs and Health it promotes the health and safety of the population by regulating medicinal, blood and tissue products, and by developing the pharmaceuticals sector.
  • https://www.stm.fi/ The Ministry of Social Affairs and Health
  • fimea.fi Finnish Medicines Agency Fimea
  • thl.fi National Institute for Health and Welfare
  • ttl.fi Finnish Institute of Occupational Health
  • tyosuojelu.fi Työsuojeluhallinto
  • valvira.fi National Authority for Welfare and Health
  • stuk.fi Radiation and Nuclear Safety Authority Radiation and Nuclear Safety Authority